Analysts Give Aurinia Pharmaceuticals a ‘Moderate Buy’ Rating
December 26, 2022
Trending News 🌥️
Aurinia Pharmaceuticals Intrinsic Value – Aurinia Pharmaceuticals ($NASDAQ:AUPH) Inc. is a publicly-traded biopharmaceutical company focused on developing and commercializing innovative therapies to treat serious diseases. Located in Victoria, British Columbia, Canada, Aurinia develops drugs that target the underlying causes of disease by modulating the immune system to maintain or restore healthy tissue and organ function. The company is currently focused on developing its lead drug candidate, voclosporin, for the treatment of lupus nephritis (LN). Recently, Bloomberg has reported that the six brokerages covering Aurinia Pharmaceuticals Inc. have given it an average rating of “Moderate Buy”. This rating reflects the brokerages’ opinion that Aurinia’s stock is likely to appreciate but also carries a significant amount of risk. Analysts are bullish on Aurinia’s prospects due to the promising clinical trial results of voclosporin for the treatment of LN.
Additionally, Aurinia’s strong balance sheet and cash position provide a solid foundation for further clinical studies and commercialization efforts. Given the current positive sentiment towards Aurinia, analysts have suggested that investors with a moderate risk tolerance should consider buying the stock. Investors should note that the “Moderate Buy” rating comes with a certain amount of risk and should conduct their own due diligence before making any investment decisions. Nevertheless, Aurinia Pharmaceuticals Inc. appears to be an attractive investment opportunity for those looking for potential growth in the biopharmaceutical sector.
Stock Price
Analysts have given Aurinia Pharmaceuticals Inc. a ‘Moderate Buy’ rating on Monday. The company’s stock opened at $4.6 and closed at $4.5, signaling a 2.6% decrease from its previous closing price of 4.6. Despite the dip, analysts remain confident in the company’s future performance. The ‘Moderate Buy’ rating is based on a 1-5 scale, with 1 being a strong buy and 5 being a strong sell.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of drugs to treat autoimmune diseases such as lupus nephritis. Given the positive outlook of the company’s drug development and its promising share price, analysts are giving Aurinia Pharmaceuticals Inc. a ‘Moderate Buy’ rating. Investors should consider this rating when making decisions about investing in Aurinia Pharmaceuticals Inc. stock. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Aurinia Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 129 | -115.46 | -89.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Aurinia Pharmaceuticals. More…
| Operations | Investing | Financing |
| -115.9 | -63.1 | 207.47 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Aurinia Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 488.29 | 64.87 | 2.98 |
Key Ratios Snapshot
Some of the financial key ratios for Aurinia Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 640.3% | – | -90.0% |
| FCF Margin | ROE | ROA |
| -90.1% | -17.1% | -14.9% |
VI Analysis – Aurinia Pharmaceuticals Intrinsic Value Calculator
The VI app simplifies the analysis of this company and provides a fair value for its stock at around $1666.6. Currently, AURINIA PHARMACEUTICALS stock is trading at $4.5 which is well below its fair value and represents a huge 100% undervaluation. Investors can take advantage of this opportunity to buy AURINIA PHARMACEUTICALS stock at a discounted rate and benefit from the potential long-term gains that can be made. The fundamentals of the company show that it is a strong investment option and should be taken into consideration when making decisions on investments. Additionally, the VI app provides investors with a comprehensive analysis of the company, which includes an assessment of its financials, its competitive position, and its potential return on investment. This helps investors to make informed decisions about their investments, ensuring that they make wise choices in order to maximize their returns. Overall, AURINIA PHARMACEUTICALS is an attractive investment option due to its strong fundamentals, and its current undervaluation of 100%. Investors should take advantage of this opportunity to buy AURINIA PHARMACEUTICALS stock at a discounted rate and benefit from the potential long-term gains that can be made. More…
VI Peers
The company’s lead candidate, voclosporin, is a novel, potentially first-in-class immunomodulatory drug that is being investigated for the treatment of lupus nephritis and other autoimmune diseases. Aurinia is also developing an oral formulation of voclosporin for the treatment of uveitis. Pieris Pharmaceuticals Inc, Vaxart Inc, MediWound Ltd are Aurinia’s main competitors in the market.
– Pieris Pharmaceuticals Inc ($NASDAQ:PIRS)
Pieris Pharmaceuticals Inc is a publicly traded company with a market capitalization of $74.41M as of March 2022. The company has a Return on Equity of -89.14%. Pieris Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of Anticalin proteins to treat a variety of respiratory diseases, including asthma, COPD, and cystic fibrosis.
– Vaxart Inc ($NASDAQ:VXRT)
Vaxart Inc is a clinical-stage biotechnology company focused on the development and commercialization of oral recombinant vaccines. The company’s vaccine candidates are based on its proprietary platform, which is designed to generate vaccine candidates to target a broad range of diseases. Vaxart’s lead program is a vaccine candidate against human papillomavirus (HPV). The company is also developing vaccine candidates against influenza and norovirus.
– MediWound Ltd ($NASDAQ:MDWD)
MediWound Ltd is a global biopharmaceutical company that develops, manufactures, and markets innovative therapeutics to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. The company has a market capitalization of 56.19 million as of 2022 and a return on equity of 193.32%. MediWound was founded in 2000 and is headquartered in Yavne, Israel.
Summary
Investing in Aurinia Pharmaceuticals Inc. can be a rewarding experience for those looking to diversify their portfolio. The company is focused on developing innovative treatments for autoimmune diseases and other serious conditions. They have a diverse pipeline of products and a strong commitment to research and development. The company has received a “Moderate Buy” rating from analysts, which suggests that the stock is fairly valued and has potential for growth. When considering investing in Aurinia Pharmaceuticals Inc., it’s important to understand their business model and what products they offer. Aurinia Pharmaceuticals Inc. focuses on developing treatments for autoimmune diseases and other serious conditions. Their goal is to bring these treatments to market in order to improve the lives of those suffering from these diseases. To do this, the company invests heavily in research and development. They also partner with other companies to leverage their expertise and resources in order to bring these treatments to the market. In addition to research and development, Aurinia Pharmaceuticals Inc. also has a comprehensive commercialization strategy. This strategy involves marketing, pricing, and distribution of their products. As part of this strategy, the company is focused on educating healthcare professionals and patients about their products and services. For those considering investing in Aurinia Pharmaceuticals Inc., it’s important to understand the risks associated with investing in pharmaceutical stocks. Investing in a pharmaceutical company carries more risk than investing in other industries because of the long-term timeline associated with drug development and regulatory approval.
Additionally, there is no guarantee that a drug will be approved or that it will be successful in the marketplace. It’s important for investors to understand that investing in pharmaceutical stocks is a long-term commitment, and it’s important to do research before investing.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
